Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies

References

• AletahaDNeogiTSilmanAJ2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
   PubMed Web of Science ®Google Scholar
• ScottDLWolfeFHuizingaTWJRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldEULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• BykerkVPAkhavanPHazlewoodGSCanadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugsJ Rheumatol20123981559158221921096
   PubMed Web of Science ®Google Scholar
• Pfizer News and Media – Press ReleasesPfizer provides update on global regulatory approvals and launches of Xeljanz^® (tofacitinib citrate) for the treatment of rheumatoid arthritis2013715 Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_provides_update_on_global_regulatory_approvals_and_launches_of_xeljanz_tofacitinib_citrate_for_the_treatment_of_rheumatoid_arthritisAccessed July 20, 2015
   Google Scholar
• European Medicines Agency – Find Medicine – Human Medicines – Pending EC DecisionsXeljanz Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_smop_000501.jsp&mid=WC0b01ac058001d127Accessed July 20, 2015
   Google Scholar
• Pfizer – News and Media – Press ReleasesPfizer builds upon robust body of knowledge for XELJANZ^® (tofacitinib citrate) with clinical trial and real-world use data at the European League Against Rheumatism Annual Congress (EULAR 2015) Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizerAccessed October 15, 2015
   Google Scholar
• Xeljanz® (tofacitinib) film coated tablet [prescribing information]New YorkPfizer Labs2015
   Google Scholar
• Pfizer Financial Reports [homepage on the internet]United States: 2014 Annual report to Shareholder: Financial report Available from: http://www.pfizer.com/investors/financial_reports/financial_reportsAccessed July 7, 2015
   Google Scholar
• Pfizer Press Release [homepage on internet]Pfizer reports first-quarter 2015 results Available from: http://www.pfizer.com/system/files/presentation/Q1_2015_PFE_Earnings_Press_Release_foijsdflskd.pdfAccessed July 7, 2015
   Google Scholar
• SongGGBaeSCLeeYHEfficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trialsKorean J Intern Med201429565666325228842
   PubMed Web of Science ®Google Scholar
• RamiroSGaujoux-VialaCNamJLSafety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis201473352953524401994
   PubMed Web of Science ®Google Scholar
• ZhangXLiangFYinXTofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysisClin Rheumatol201433216517324389749
   PubMed Web of Science ®Google Scholar
• SalgadoEManeiroJRCarmonaLGomez-ReinoJJSafety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysisAnn Rheum Dis201473587188223599436
   PubMed Web of Science ®Google Scholar
• BerhanAEfficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studiesBMC Musculoskelet Disord20131433224279308
   PubMed Web of Science ®Google Scholar
• HeYWongAYChanEWEfficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysisBMC Musculoskelet Disord20131429824139404
   PubMed Web of Science ®Google Scholar
• KawalecPMikrutAWiśniewskaNPilcAThe effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysisClin Rheumatol201332101415142423877486
   PubMed Web of Science ®Google Scholar
• VyasDO’DellKMBandyJLBoyceEGTofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritisAnn Pharmacother201347111524153124285764
   PubMed Web of Science ®Google Scholar
• O’DellKMRummelAETofacitinib: a novel oral Janus kinase inhibitor for rheumatoid arthritisFormulary20124710350358
   Google Scholar
• AndersonJCaplanLYazdanyJRheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practiceArthritis Care Res (Hoboken)2012645660667
   Web of Science ®Google Scholar
• MaskaLAndersonJMichaudKMeasures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)Arthritis Care Res (Hoboken)201163Suppl 11S4S1322588760
   PubMed Web of Science ®Google Scholar
• CellaDYountSSorensenMChartashESenguptaNGroberJValidation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritisJ Rheumatol200532581181915868614
   PubMed Web of Science ®Google Scholar
• PincusTThe American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritisClin Exp Rheumatol2005235 Suppl 39S109S11316273794
   PubMed Web of Science ®Google Scholar
• KremerJMBloomBJBreedveldFCThe safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placeboArthritis Rheum20096071895190519565475
   PubMed Web of Science ®Google Scholar
• CoombsJHBloomBJBreedveldFCImproved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trialAnn Rheum Dis201069241341619587388
   PubMed Web of Science ®Google Scholar
• TanakaYSuzukiMNakamuraHToyoizumiSZwillichSHTofacitinib Study InvestigatorsPhase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexateArthritis Care Res (Hoboken)20116381150115821584942
   PubMed Web of Science ®Google Scholar
• FleischmannRCutoloMGenoveseMCA phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsArthritis Rheum201264361762921952978
   PubMed Web of Science ®Google Scholar
• KremerJMCohenSWilkinsonBEA phase IIb dose-ranging study of the ORAL JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneArthritis Rheum201264497098122006202
   PubMed Web of Science ®Google Scholar
• FleischmannRKremerJCushJORAL Solo InvestigatorsPlacebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisN Engl J Med2012367649550722873530
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFFleischmannRCohenSORAL Standard InvestigatorsTofacitinib or adalimumab versus placebo in rheumatoid arthritisN Engl J Med2012367650851922873531
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDTanakaYFleischmannORAL Scan InvestigatorsTofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyArthritis Rheum201365355957023348607
   PubMed Web of Science ®Google Scholar
• BurmesterGRBlancoRCharles-SchoemanCORAL Step InvestigatorsTofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trialLancet2013381986545146023294500
   PubMed Web of Science ®Google Scholar
• KremerJLiZGHallSTofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialAnn Intern Med2013159425326124026258
   PubMed Web of Science ®Google Scholar
• LeeEBFleischmannRHallSORAL Start InvestigatorsTofacitinib versus methotrexate in rheumatoid arthritisN Engl J Med2014370252377238624941177
   PubMed Web of Science ®Google Scholar
• WollenhauptJSilverfieldJLeeEBSafety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studiesJ Rheumatol201441583785224692527
   PubMed Web of Science ®Google Scholar
• StrandVBurmesterGRZerbiniCAFTofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trialArthritis Care Res (Hoboken)201567447548325186034
   PubMed Web of Science ®Google Scholar
• TanakaYTakeuchiTYamanakaHNakamuraHToyoizumiSZwillichSEfficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 studyMod Rheumatol201525451452125496464
   PubMed Web of Science ®Google Scholar
• CohenSZwillichSHChowVLabadieRRWilkinsonBCo-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentBr J Clin Pharmacol201069214315120233177
   PubMed Web of Science ®Google Scholar
• CohenSRadominskiSCGomez-ReinoJJAnalysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisArthritis Rheumatol201466112924293725047021
   PubMed Web of Science ®Google Scholar
• CurtisJRLeeEBKaplanIVTofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeAnn Rheum Dis Epub2015422
   Google Scholar
• WinthropKLSilverfieldJRacewiczAThe effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritisAnn Rheum Dis Epub2015320
   Google Scholar
• SolomonDHCurtisJRSaagKGCardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDsAm J Med20131268730.e9730.e1723885678
   PubMed Web of Science ®Google Scholar
• SoutoASalfadoEManieroJRMeraACarmonaLGomez-ReinoJJLipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysisArthritis Rheumatol201567111712725303044
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration – News and Events – FDA News ReleaseFDA approves Xeljanz for rheumatoid arthritis Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htmAccessed October 15, 2015
   Google Scholar
• RoubilleCRicherVStarninoTThe effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysisAnn Rheum Dis201574348048925561362
   PubMed Web of Science ®Google Scholar